100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

New Insights into Microscopy

Watch the recording of our free webinar.

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

Many discontinue obesity medication – new study highlights the reasons

A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses hea...

Eli Lilly Recruits Leading Swedish Researcher Kaj Blennow to Head Alzheimer’s Project

Eli Lilly recruits Kaj Blennow, leading Alzheimer’s researcher, as VP of neuroscience biomarker development.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

The Covid pandemic accelerated the development of cancer vaccine

The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast ...

ZEISS receives FDA clearance for INTRABEAM 700

With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.

Här är topp fem dyraste läkemedlen 2025

Nya avancerade terapiläkemedel når marknaden, men prislapparna är höga. På årets lista över de dyraste läkemedlen i USA finns en gemensam nämnare: alla är gente...

A cluster contribution to European life science innovation and competitiveness?

FDA plans to replace animal testing with AI – “Paradigm shift”

The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Join us for a Life Science seminar on april 9th on GoCo

Festo products and solutions are setting the stage for better health through innovative solutions for reliable medical technology and precise, reproducible labo...

GSK acquires oncology research company

GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.

Xbrane backar efter ny FDA-smäll – ”Vi är mycket besvikna”

Xbrane Biopharma backar med över 30 procent på börsen efter fortsatta problem hos en kontraktstillverkare – vilket väntas leda till ytterligare förseningar av e...

Trögt för genterapi mot blödarsjuka – kan dumpas av bolaget

Roctavian, en genterapi mot blödarsjuka som sågs som ett medicinsk genombrott, har floppat kommersiellt. Nu planerar företaget bakom att avyttra läkemedlet från sin portfölj.

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...

Kanada godkänner Leqembi – racet om alzheimerläkemedel hårdnar

Leqembi får godkännande i Kanada och stärker därmed sitt globala försprång. Läkemedlet är nu godkänt på 15 större marknader – en mer än rivalen Kisunla.

Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...